HBV
MCID: HPT016
MIFTS: 63

Hepatitis B (HBV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis B

MalaCards integrated aliases for Hepatitis B:

Name: Hepatitis B 12 75 55 43 44 15 38 72
Hepatitis B Infection 12 15 17
Hepatitis B, Chronic 72
Chronic Hepatitis B 12
Hepatitis B Chronic 55
Serum Hepatitis 12
Hbv 48

Classifications:



External Ids:

Disease Ontology 12 DOID:2043
MeSH 44 D006509
NCIt 50 C3097
SNOMED-CT 68 66071002
UMLS 72 C0019163 C0524909

Summaries for Hepatitis B

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. One type, hepatitis B, is caused by the hepatitis B virus (HBV). Hepatitis B spreads by contact with an infected person's blood, semen, or other body fluid. An infected woman can give hepatitis B to her baby at birth. If you get HBV, you may feel as if you have the flu. You may also have jaundice, a yellowing of skin and eyes, dark-colored urine, and pale bowel movements. Some people have no symptoms at all. A blood test can tell if you have it. HBV usually gets better on its own after a few months. If it does not get better, it is called chronic HBV, which lasts a lifetime. Chronic HBV can lead to cirrhosis (scarring of the liver), liver failure, or liver cancer. There is a vaccine for HBV. It requires three shots. All babies should get the vaccine, but older children and adults can get it too. If you travel to countries where Hepatitis B is common, you should get the vaccine. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Hepatitis B, also known as hepatitis b infection, is related to hepatitis d and liver disease, and has symptoms including fever, vomiting and fatigue. An important gene associated with Hepatitis B is MIR21 (MicroRNA 21), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Human cytomegalovirus infection. The drugs Alprostadil and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, liver and testes, and related phenotype is neoplasm.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis B virus, which is transmitted by sexual contact, transmitted by blood transfusions, and transmitted by fomites like needles or syringes. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia : 75 Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver. It... more...

Related Diseases for Hepatitis B

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis B via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1176)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 34.1 IFNA2 GPT F2
2 liver disease 32.6 TNF IFNA1 GPT F2 ALB AFP
3 viral hepatitis 32.4 TNF IFNA2 IFNA1 GPT F2 ALB
4 hepatitis 32.2 TNF SLC10A1 RSF1 NR5A2 LAMTOR5 IFNAR2
5 hepatitis c 32.1 TNF IFNG IFNAR2 IFNA2 IFNA1 GPT
6 human immunodeficiency virus infectious disease 32.0 TNF IFNG IFNA1 APOBEC3G
7 acute liver failure 31.9 GPT F2 ALB
8 liver cirrhosis 31.9 IFNA1 GPT F2 ALB AFP
9 viral infectious disease 31.8 TNF IFNG IFNA2 IFNA1 GPT
10 hepatic coma 31.7 GPT F2 ALB
11 acquired immunodeficiency syndrome 31.5 TNF IFNG IFNA2 IFNA1 ALB
12 hepatic encephalopathy 31.5 TNF GPT F2 ALB
13 mumps 31.5 TNF IFNG IFNAR2
14 cryoglobulinemia, familial mixed 31.5 IFNA2 IFNA1
15 severe acute respiratory syndrome 31.5 TNF IFNG IFNA1
16 demyelinating disease 31.5 TNF IFNG IFNA1
17 proteasome-associated autoinflammatory syndrome 1 31.4 TNF IFNG ALB
18 hepatitis e 31.4 TNF IFNG GPT F2 ALB
19 portal hypertension 31.3 TNF GPT F2 ALB
20 bacterial infectious disease 31.3 TNF MBL2 IFNG
21 schistosomiasis 31.3 TNF IFNG F2 ALB
22 measles 31.3 IFNG IFNAR2 IFNA1
23 peritonitis 31.3 TNF F2 ALB
24 chronic graft versus host disease 31.3 TNF IFNG ALB
25 rheumatic disease 31.3 TNF IFNG IFNA1
26 pulmonary tuberculosis 31.3 TNF MBL2 IFNG
27 mouth disease 31.2 TNF IFNG IFNA1
28 hepatitis a 31.2 TNF IFNG GPT F2 ALB AFP
29 uveitis 31.1 TNF IFNG IFNA2
30 bilirubin metabolic disorder 31.1 GPT F2 ALB
31 biliary atresia 31.0 SLC10A1 GPT ALB
32 aspergillosis 30.9 TNF MBL2 IFNG
33 esophageal varix 30.9 F2 ALB AFP
34 hypersplenism 30.9 IFNG F2 ALB
35 alcoholic hepatitis 30.8 TNF GPT F2 ALB
36 non-a-e hepatitis 30.8 F2 ALB
37 cholecystitis 30.8 GPT F2 ALB
38 visceral leishmaniasis 30.8 TNF IFNG ALB
39 cholangitis 30.8 TNF GPT F2 ALB
40 meningitis 30.8 TNF MBL2 IFNG ALB
41 eclampsia 30.6 TNF F2 ALB
42 systemic lupus erythematosus 30.6 TNF MBL2 IFNG IFNA1 F2 ALB
43 hemangioma of liver 30.6 IFNA2 F2
44 gastroenteritis 30.6 TNF IFNA1 ALB
45 infantile liver failure syndrome 1 30.6 GPT F2 ALB
46 filariasis 30.5 TNF IFNG ALB
47 cerebral palsy 30.5 TNF MBL2 F2
48 opisthorchiasis 30.5 TNF GPT AFP
49 leptospirosis 30.4 TNF IFNG F2
50 alcoholic liver cirrhosis 30.4 F2 ALB AFP

Graphical network of the top 20 diseases related to Hepatitis B:



Diseases related to Hepatitis B

Symptoms & Phenotypes for Hepatitis B

Symptoms:

12
  • fever
  • vomiting
  • fatigue
  • abdominal pain
  • jaundice
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis B:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatitis B:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 AFP AIP ALB IFNAR2 IFNG TNF

Drugs & Therapeutics for Hepatitis B

Drugs for Hepatitis B (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 572)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
4
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
5
Simethicone Approved Phase 4 8050-81-5
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7
Ribavirin Approved Phase 4 36791-04-5 37542
8
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
9
Zidovudine Approved Phase 4 30516-87-1 35370
10
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
11
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
12
Pentetic acid Approved Phase 4 67-43-6
13
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
14
Adalimumab Approved Phase 4 331731-18-1 16219006
15
Azathioprine Approved Phase 4 446-86-6 2265
16
Etanercept Approved, Investigational Phase 4 185243-69-0
17
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
18
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
19
Polyestradiol phosphate Approved Phase 4 28014-46-2
20
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
21
Saxagliptin Approved Phase 4 361442-04-8 11243969
22
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
23
Cobicistat Approved Phase 4 1004316-88-4
24
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
25
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
26 Vedolizumab Approved Phase 4 943609-66-3
27
Metformin Approved Phase 4 657-24-9 4091 14219
28
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
29
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
30
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Methadone Approved, Illicit Phase 4 76-99-3 4095
33
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
34
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
35
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
36
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
37
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
38
Ornithine Approved, Nutraceutical Phase 4 70-26-8, 3184-13-2 6262
39
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
40
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
42
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
43
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
44
Enoxolone Investigational Phase 4 471-53-4 18526330
45
Thymalfasin Investigational Phase 4 62304-98-7
46
Clevudine Investigational Phase 4 163252-36-6
47 Lipid Regulating Agents Phase 4
48 Hypolipidemic Agents Phase 4
49 Polyene phosphatidylcholine Phase 4
50 Lecithin Phase 4

Interventional clinical trials:

(show top 50) (show all 1889)
# Name Status NCT ID Phase Drugs
1 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
2 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
3 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
4 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
5 Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study) Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
6 Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults. Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
7 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study Unknown status NCT01829685 Phase 4 Entecavir, Adefovir
8 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
9 PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab Unknown status NCT02523547 Phase 4 Cavir;Baraclude
10 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
11 The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B. Unknown status NCT03208998 Phase 4 Peginterferon Alfa-2a
12 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
13 Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
14 A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study Unknown status NCT01834508 Phase 4 oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
15 The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209037 Phase 4 Peginterferon Alfa-2a
16 The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B Unknown status NCT03209011 Phase 4 Peginterferon Alfa-2a
17 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
18 A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
19 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
20 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
21 A Multi-center, Open Label, Randomized Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Capsule Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
22 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
23 AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (Presumed Pre-Core Mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN. Unknown status NCT00354653 Phase 4 LAMIVUDINE
24 The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
25 A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: Unknown status NCT01456312 Phase 4 Peginterferon alfa-2a;Entecavir
26 Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
27 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
28 A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy Unknown status NCT02594293 Phase 4 PegIFN alfa-2a
29 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection. Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
30 Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment Unknown status NCT02365402 Phase 4 Entecavir
31 A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection Unknown status NCT00939068 Phase 4 Telbivudine
32 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
33 Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a Unknown status NCT02368288 Phase 4 entecavir
34 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
35 A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
36 Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy Unknown status NCT02081469 Phase 4
37 HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
38 A 3-year, Open-label, Multi-center Extension Trial of Telbivudine Therapy for Patients Previously Treated in EFFORT Clinical Trial Unknown status NCT01529255 Phase 4 telbivudine (ROADMAP);Telbivudine (Standard of Care)
39 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4 Entecavir and peginterferon alfa-2a;Placebo and peginterferon
40 Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4 Entecavir and peginterferon (Pegasys) (52 weeks);Peginterferon (Pegasys) (96 weeks);Peginterferon (Pegasys) (48 weeks)
41 A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml. Unknown status NCT02894918 Phase 4 Peginterferon alfa-2a
42 A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks Unknown status NCT02474316 Phase 4 Peginterferon alfa-2a;nucleos(t)ide analgoue
43 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
44 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
45 Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
46 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
47 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
48 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
49 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of "Response-Guided-Therapy (RGT)" Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients Unknown status NCT02560649 Phase 4 Peginterferon alfa-2a plus Entecavir;Peginterferon alfa-2a plus Lamivudine;Peginterferon alfa-2a plus Adefovir;Peginterferon alfa-2a plus Tenofovir;Entecavir;Lamivudine;Adefovir;Tenofovir disoproxil
50 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming

Search NIH Clinical Center for Hepatitis B

Inferred drug relations via UMLS 72 / NDF-RT 51 :


adefovir
adefovir dipivoxil
Adefovir dipivoxil
entecavir
Entecavir
Hepatitis B Immune Globulin
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
Interferon Alfa-2b
Lamivudine
Lamivudine
Peginterferon alfa-2a
telbivudine
Telbivudine
Tenofovir
Tenofovir alafenamide
tenofovir alafenamide fumarate
Tenofovir disoproxil
Tenofovir disoproxil fumarate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis B cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis B:
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Hepatitis B:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: hepatitis b

Genetic Tests for Hepatitis B

Anatomical Context for Hepatitis B

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis B:

19
Liver

MalaCards organs/tissues related to Hepatitis B:

41
Liver, Testes, T Cells, Kidney, Bone, B Cells, Bone Marrow

Publications for Hepatitis B

Articles related to Hepatitis B:

(show top 50) (show all 32478)
# Title Authors PMID Year
1
Screening for Hepatitis B in Pregnant Women. 38 17
31334796 2019
2
Anesthesiologists' acquisition of hepatitis B virus infection: Risk and prevention. 38 17
31335690 2019
3
Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China. 17
31393369 2019
4
Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. 9 38
20304099 2010
5
Effect of maternal hepatitis B carrier status on first-trimester markers of Down syndrome. 9 38
20332164 2010
6
Plasma levels of trace elements have an implication on interferon treatment of children with chronic hepatitis B infection. 9 38
19727570 2010
7
Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. 9 38
20155784 2010
8
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 9 38
20209613 2010
9
Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? 9 38
20162620 2010
10
Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. 9 38
20107884 2010
11
Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. 9 38
20070399 2010
12
Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. 9 38
20022949 2010
13
The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication. 9 38
20053744 2010
14
Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. 9 38
19857525 2010
15
A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. 9 38
20137825 2010
16
Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. 9 38
20091678 2010
17
Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. 9 38
19900483 2010
18
NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. 9 38
20010875 2010
19
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. 9 38
20101751 2010
20
Occult hepatitis B virus infection: a covert operation. 9 38
20002296 2010
21
Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. 9 38
20030580 2010
22
Nutritional status of children with chronic hepatitis B in a population with low socioeconomic status. 9 38
19458532 2009
23
Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. 9 38
19626651 2009
24
[Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment]. 9 38
19785947 2009
25
Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. 9 38
19585616 2009
26
The correlation of hepatocyte nuclear factor 4 alpha and 3 beta with hepatitis B virus replication in the liver of chronic hepatitis B patients. 9 38
19302415 2009
27
Antiviral therapy for chronic hepatitis B: are we doing any good to patients? 9 38
19468026 2009
28
Household survey of hepatitis B vaccine coverage among Brazilian children. 9 38
19616495 2009
29
Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. 9 38
19263472 2009
30
[Hepatitis B virus X protein upregulates the transcription activity of zinc finger transcription factor SNAI1]. 9 38
19671315 2009
31
CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. 9 38
19403062 2009
32
Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. 9 38
19208347 2009
33
Gene expression profiles of human liver cells mediated by hepatitis B virus X protein. 9 38
19343061 2009
34
Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. 9 38
19105208 2009
35
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. 9 38
19220736 2009
36
[Dynamic changes of Th1/Th2 type cytokines in peripheral blood of patients with hepatitis B e antigen-positive chronic hepatitis B treated with telbivudine]. 9 38
19335978 2009
37
[Expression of interleukin-17 in hepatitis B related liver fibrosis]. 9 38
19174010 2009
38
Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. 9 38
18662281 2009
39
Hepatitis B therapy in children. 9 38
19210112 2009
40
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. 9 38
20032548 2009
41
[A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B]. 9 38
19203448 2009
42
A review of the natural history of chronic hepatitis B in the era of transient elastography. 9 38
19578234 2009
43
Bicyclol: a novel drug for treating chronic viral hepatitis B and C. 9 38
19149648 2009
44
Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. 9 38
19812443 2009
45
Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. 9 38
19704174 2009
46
The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. 9 38
18465238 2008
47
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. 9 38
19052126 2008
48
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. 9 38
18840078 2008
49
Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. 9 38
18823435 2008
50
Hepatitis B virus-induced hFGL2 transcription is dependent on c-Ets-2 and MAPK signal pathway. 9 38
18801734 2008

Variations for Hepatitis B

Expression for Hepatitis B

Search GEO for disease gene expression data for Hepatitis B.

Pathways for Hepatitis B

Pathways related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 TNF MBL2 IFNG IFNAR2 IFNA2 IFNA1
2
Show member pathways
12.77 TNF LAMTOR5 IFNAR2 IFNA2 IFNA1 APOBEC3G
3
Show member pathways
12.34 IFNG IFNAR2 IFNA2 IFNA1
4
Show member pathways
12.2 IFNG IFNAR2 IFNA2 IFNA1
5
Show member pathways
12.15 TNF IFNG F2 ALB
6
Show member pathways
12.08 IFNG IFNAR2 IFNA2 IFNA1
7
Show member pathways
12.03 TNF IFNG IFNAR2 IFNA2 IFNA1
8 11.96 TNF IFNG IFNA2 IFNA1
9
Show member pathways
11.86 TNF IFNG IFNAR2 IFNA2 IFNA1
10 11.57 TNF IFNG IFNA2
11
Show member pathways
11.42 TNF IFNG IFNAR2
12
Show member pathways
11.26 TNF IFNG IFNAR2 IFNA2 IFNA1
13 11.23 TNF IFNG AIP
14 11.2 IFNG IFNAR2 IFNA2 IFNA1
15 11.14 F2 ALB AFP

GO Terms for Hepatitis B

Cellular components related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 TNF MBL2 IFNG IFNAR2 IFNA2 IFNA1
2 extracellular space GO:0005615 9.44 TNF MIR301A MIR21 MIR17 MBL2 IFNG

Biological processes related to Hepatitis B according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.88 TNF IFNAR2 IFNA2 IFNA1
2 cell surface receptor signaling pathway GO:0007166 9.87 IFNG IFNAR2 IFNA2 F2
3 positive regulation of protein phosphorylation GO:0001934 9.81 TNF MIR21 IFNG F2
4 negative regulation of gene expression GO:0010629 9.77 TNF MIR21 MIR17 IFNG IFNA2
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.73 TNF MIR21 F2
6 type I interferon signaling pathway GO:0060337 9.71 IFNAR2 IFNA2 IFNA1
7 response to virus GO:0009615 9.71 TNF LAMTOR5 IFNG IFNAR2
8 positive regulation of phagocytosis GO:0050766 9.63 TNF MIR17 MBL2
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.6 MIR21 MIR17
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.59 TNF IFNG
11 negative regulation of growth of symbiont in host GO:0044130 9.58 TNF MBL2
12 positive regulation of metalloendopeptidase activity GO:1904685 9.55 MIR21 MIR17
13 defense response to virus GO:0051607 9.55 IFNG IFNAR2 IFNA2 IFNA1 APOBEC3G
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.52 MIR21 MIR17
15 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.49 TNF MIR21
16 negative regulation of viral process GO:0048525 9.48 MBL2 APOBEC3G
17 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IFNG
18 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.43 IFNG IFNA2 IFNA1
19 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 TNF IFNG
20 humoral immune response GO:0006959 9.26 TNF IFNG IFNA2 IFNA1
21 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.92 TNF MIR301A MIR21 MIR17

Molecular functions related to Hepatitis B according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 type I interferon receptor binding GO:0005132 8.96 IFNA2 IFNA1
2 cytokine activity GO:0005125 8.92 TNF IFNG IFNA2 IFNA1

Sources for Hepatitis B

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....